Form 4: CYTOKINETICS EVP Callos Receives Equity Awards

Cytokinetics' EVP and Chief Commercial Officer, Andrew Callos, was granted significant equity awards, including restricted stock units and stock options, effective March 15, 2026.

Summary

• Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc. (CYTK), reported the acquisition of equity awards.
• He was granted 20,646 restricted stock units (RSUs) as an annual equity award, which convert on a 1:1 basis for common stock. These RSUs vest 40% on the 1-year anniversary, an additional 40% on the 2-year anniversary, and the final 20% on the 3-year anniversary of the grant date, subject to continued employment.
• A special supplemental equity award of 13,320 restricted stock units (RSUs) was also granted, vesting 50% on the 1-year anniversary and 50% on the 2-year anniversary of the grant date, subject to continued employment.
• Callos also received an annual equity award of 1,665 Incentive Stock Options (right to buy) with an exercise price of $60.06. These options vest in 48 equal monthly installments, subject to continued employment.
• Additionally, 29,480 Non-Qualified Stock Options (right to buy) were granted as an annual equity award, also with an exercise price of $60.06 and vesting in 48 equal monthly installments, subject to continued employment.
• All equity awards are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
• Following these transactions, Callos beneficially owns 81,824 shares of Common Stock, 1,665 Incentive Stock Options, and 29,480 Non-Qualified Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for executive retention and alignment, reflecting standard compensation practices for a key officer, which generally supports stable management and long-term strategic execution.

Positives

• The grants represent a significant equity award to a key executive, aligning management's interests with long-term shareholder value.
• The awards are part of a Rule 10b5-1(c) plan, indicating a pre-arranged, systematic approach to executive compensation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedules and expiration dates of the granted equity awards.

Industry Context

StockSavvy.ai notes that equity awards are a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their interests with long-term shareholder value. The use of a Rule 10b5-1 plan for these transactions is also standard practice for insiders to manage their equity holdings in compliance with insider trading regulations.

Comparison to Industry Standards

• StockSavvy.ai observes that the vesting schedules (1-3 years for RSUs, 48 months for options) are typical for executive equity compensation in the biotech sector, comparable to practices at companies like Amgen or Gilead Sciences, designed to encourage long-term commitment and retention.
• The grant of both RSUs and stock options is a common dual-pronged approach in executive compensation, balancing immediate value (RSUs) with long-term growth incentives (options).

Stakeholder Impact

• Shareholders: Potential future dilution from the conversion of RSUs and exercise of stock options, but also increased alignment of executive interests with long-term shareholder value.
• Employees: No direct impact on general employees is mentioned, but the executive compensation structure may influence overall company compensation philosophy.

Next Steps

• Vesting of the 20,646 annual RSUs will occur on the 1-year, 2-year, and 3-year anniversaries of the grant date.
• Vesting of the 13,320 supplemental RSUs will occur on the 1-year and 2-year anniversaries of the grant date.
• The 1,665 Incentive Stock Options and 29,480 Non-Qualified Stock Options will vest in 48 equal monthly installments, beginning April 15, 2026.

Key Dates

Recommendation

This Form 4 reports routine executive compensation in the form of equity awards, which is a standard practice for retaining and incentivizing key personnel. It does not present new information that would significantly alter the investment thesis for Cytokinetics, hence a 'hold' recommendation is appropriate for existing investors.

Keywords

Cytokinetics, CYTK, Andrew Callos, Form 4, SEC filing, equity award, RSU, stock option, executive compensation, insider transaction, beneficial ownership, Rule 10b5-1